成果報告書詳細
管理番号20110000001413
タイトル*平成21年度中間年報 iPS細胞等幹細胞産業応用促進基盤技術開発
公開日2011/11/23
報告書年度2009 - 2009
委託先名社団法人バイオ産業情報化コンソーシアム
プロジェクト番号P08030
部署名バイオテクノロジー・医療技術開発部
和文要約和文要約等以下本編抜粋:1. 研究開発の内容及び成果等
(1) 新規多能性誘導遺伝子の探索
既知多能性誘導遺伝子(山中4 遺伝子)を相補する新規多能性誘導因子の探索をゲノムワイドに進め、網羅的に多能性誘導遺伝子の取得を試みる。さらに、従来よりもiPS 細胞誘導効率の高い多能性誘導因子の組み合わせの探索、均一性の高いiPS 細胞を作製するための因子の組み合わせの探索を行い、安全かつ効率的な多分化能誘導遺伝子の探索を行う。20~21 年度の成果は次のとおり。
・ヒトcDNA 発現リソースから遺伝子発現調節に関与する転写因子等のカテゴリーに絞り、集中的にこれらの遺伝子群から新規多能性誘導遺伝子の探索を行い、一部の因子の代替機能をもつ新規4遺伝子を発見し、その他にも候補クローンを多数見出した。新規4 遺伝子については米国仮出願を行った後、PCT 出願を行った。更に、これらの新規4 遺伝子と既知の多能性誘導遺伝子の組合せを検討し、相乗的にiPS 細胞作製効率が上昇する方法を見出し米国仮出願を行った。相乗効果を示す因子のタンパク質レベルでの作用機作の解析もあわせて行い、今後の新規多能性誘導遺伝子の探索の指標を得た。
英文要約Title:Fundamental Research Project for Promoting Industrial Use of Stem Cells such as iPS Cells.(FY2008-FY2013)FY2009Annual Report
The progress of stem cell research, especially the success of iPS cells, indicates expectations not only in the rapid progress of the regenerative medicine but also in the application to drug development technologies using functional cells differentiated from stem cells, disease-related iPS cells. However, medical and industrial use of stem cells such as iPS cells should overcome several problems. First of all,it is the most important to make safe and stable stem cells efficiently from differentiated somatic cells. For this purpose, it is necessary to develop and confirm possible reprogramming technologies to establish animal and human iPS cells. One of issues demanded most in pharmaceutical drug industry is to predict accurately whether there is a possibility that a candidate drug under development causes human potential fatal arrhythmia (cardiac toxicity) or not. It becomes possible to select the development candidate medicines at earlier stages of drug development by developing cardiotoxicity detection system using cardiomyocytes derived from the stem cells such as human iPS cells. This drug screening system would expect to shorten the drug research and development period, to reduce cost. This technology would promote safer drug development. First in the project, development and verification of reprogramming techniques for making safe, stable stem cells efficiently has been progressed for promotion of industrial use of stem cells such as human iPS cells. Secondly, the standard methods to evaluate characteristics of established stem cells at the levels of genes, cell morphologies and cell functions are clarified, and the technology for selecting stable and functionally excellent steam cells is developed. Thirdly, the cardiotoxicity detection system using the cardiomyocyte differentiated from stem cells such as human iPS cells is developed for the screening and selection of drug candidates. This report shows results of research and development activities in the fiscal 2009 year.
ダウンロード成果報告書データベース(ユーザ登録必須)から、ダウンロードしてください。

▲トップに戻る